BCAX vs ANL โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
BCAX Captures Institutional Edge (2โ1 Pillars ยท 3โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Bicara Therapeutics Inc. Common Stock (BCAX) driven by superior Growth & Margin, Options & Structure while ANL counters with relative strength in Momentum & Technical. Fundamentally, BCAX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ANL at N/M Forward P/E and -123.5% operating margin (+178.1% YoY). In options structure, BCAX sits in BREAKDOWN (23rd %ile IV; Dealer Gamma Walls on Pro) against ANL sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | BCAX | ANL | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $665.2M | $683.3M | Larger Scale | ANL |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +178.1% | Higher Growth | ANL |
| Operating Margin (TTM) Profitability | 0.0% | -123.5% | Higher Margin | BCAX |
| Net Profit Margin Profitability | 0.0% | -124.8% | Higher Margin | BCAX |
| Return on Equity (ROE) Capital Efficiency | -54.2% | -20.2% | Higher ROE | ANL |
| 52-Week Range Position Momentum | 8% ($8โ$31) | 56% ($1โ$17) | Stronger Trend | ANL |
| Beta / 30D Volatility Risk Regime | 1.42ฮฒ ยท 184% Vol | 2.64ฮฒ ยท 81% Vol | Lower Realized Risk | ANL |
| Unified Institutional Score Composite Signal | 52.1 / 100 (HOLD) | 48.3 / 100 (HOLD) | Higher Composite | BCAX |